<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547699</url>
  </required_header>
  <id_info>
    <org_study_id>Cytokine plus Global Protein</org_study_id>
    <nct_id>NCT04547699</nct_id>
  </id_info>
  <brief_title>Cytokines Supplementation to Culture Media and ICSI Outcome</brief_title>
  <official_title>Impact of Cytokine Supplementation With Various Protein Concentrations Into Human in Vitro Culture Medium on ICSI Cycle Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura Integrated Fertility Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rahem Fertility Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mansoura Integrated Fertility Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial to evaluate the effect of cytokine supplementation in embryo&#xD;
      culture medium with various protein concentrations aiming to evaluate the effects of&#xD;
      cytokines (CYK) integration into the human in vitro culture medium with high and low human&#xD;
      serum albumin (HSA) concentrations on live birth rates after intracytoplasmic sperm injection&#xD;
      (ICSI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oocytes were injected, and embryos cultured and transferred in three supplemented culture&#xD;
      media.&#xD;
&#xD;
      A- A single step culture medium (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol), life global&#xD;
      protein, without supplementation of CYK (control n=200), B- A single step culture medium&#xD;
      (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol), life global protein, with 2ng/mL GM-CSF&#xD;
      (granulocyte macrophage colony stimulating factor) (G5035 Sigma), 5ng/mL HB-EGF (Heparine&#xD;
      Binding Epidermal Growth Factor )(E4643 Sigma),and 5ng/mL LIF (Lukemia Inhbitory Factor)&#xD;
      (SRP9001 Sigma)(n=200).&#xD;
&#xD;
      C- A single step culture medium (SSCM; Global, Life Global) +2mg/ml (5% Vol/Vol) life global&#xD;
      protein, with 2ng/mL GM-CSF (G5035 Sigma), 5ng/mL HB-EGF (E4643 Sigma), and 5ng/mL LIF&#xD;
      (SRP9001 Sigma).(n=200) Setting :- - Mansoura Integrated Fertility&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized, double-blinded and prospective study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>live birth rate</measure>
    <time_frame>9 months</time_frame>
    <description>the number of deliveries that resulted in at least one live born baby (&gt;20 weeks gestational age or 500 gm birth weight ) expressed per 100 embryo transfer,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>Fertilization rate (fertilized oocytes with two pronuclei/ number of MII oocytes) ×100 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Top quality day 3 embryos</measure>
    <time_frame>4 weeks</time_frame>
    <description>embryos with seven or eight blastomeres of stage-proper sizes, and &lt;10% fragmentation by volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blastocyst formation rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>(number of blastocysts/number of cultured embryos for blastocyst formation) ×100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Top blastocyst rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>(number of high quality blastocysts/number of formed blastocysts) ×100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Available embryo rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>number of transferred and frozen embryos/number of zygotes (2 pronuclei) ×100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>number of cycles with clinical pregnancy/number of transferred cycles) ×100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>number of cycles with biochemical pregnancy/number of Cycles with positive HCG) ×100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>number of implanted embryos/number of transferred embryos) ×100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early embryo loss rat</measure>
    <time_frame>16 weeks</time_frame>
    <description>number of early spontaneously aborted embryos/number of transferred embryos) × 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ongoing pregnancy rate</measure>
    <time_frame>16 weeks</time_frame>
    <description>number of clinical pregnancies after 12 weeks divided by number of embryo transfers multiplied by 100</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>ICSI</condition>
  <arm_group>
    <arm_group_label>HSA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single step culture medium (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol) life global protein,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYK+ high HSA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single step culture medium (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol) life global protein, supplemented with 2ng/mL GM-CSF (G5035 Sigma), 5ng/mL HB-EGF (E4643 Sigma),and 5ng/mL LIF (SRP9001 Sigma).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYK+low HSA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single step culture medium (SSCM; Global, Life Global) +2mg/ml (5% Vol/Vol) life global protein, supplemented with 2ng/mL GM-CSF (G5035 Sigma), 5ng/mL HB-EGF (E4643 Sigma), and 5ng/mL LIF (SRP9001 Sigma).</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>A single step culture medium</intervention_name>
    <description>A single step culture medium (SSCM; Global, Life Global)+5mg/ml life global protein, without supplementation of CYK</description>
    <arm_group_label>CYK+ high HSA</arm_group_label>
    <arm_group_label>CYK+low HSA</arm_group_label>
    <arm_group_label>HSA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who fitted the medical definition of infertility &quot;One year of unprotected&#xD;
             intercourse but not pregnant&quot;.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of ovarian or adnexal surgery.&#xD;
&#xD;
          -  Suspicious findings of ovarian malignancy.&#xD;
&#xD;
          -  Presence of endocrine disorders such as diabetes mellitus, hyper-prolactinemia,&#xD;
             thyroid dysfunction, congenital adrenal hyperplasia, Cushing's syndrome, and adrenal&#xD;
             insufficiency.&#xD;
&#xD;
          -  Presence of Globozoospermia (100% round-headed spermatozoa)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emad M Sedeek, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>MIFC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamad E Ghanem, MD</last_name>
    <phone>+201223366955</phone>
    <email>meghanem87@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emad M Sedeek, MS</last_name>
    <phone>+2001021895678</phone>
    <email>sedeek_80@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mansoura Integrated fertility Center</name>
      <address>
        <city>Mansoura</city>
        <state>Dekahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad E Ghanem, MD</last_name>
      <phone>+201223366955</phone>
      <email>meghanem87@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Emad M Sedeek, MS</last_name>
      <phone>+201021895678</phone>
      <email>dr.sedeek@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohamad E Ghanem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emad M Sedeek, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mansoura Integrated Fertility Center</name>
      <address>
        <city>Mansoura</city>
        <zip>3311</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad E Ghanem, MD</last_name>
      <phone>+201223366955</phone>
      <email>meghanem87@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Fukui Y, Hirota Y, Matsuo M, Gebril M, Akaeda S, Hiraoka T, Osuga Y. Uterine receptivity, embryo attachment, and embryo invasion: Multistep processes in embryo implantation. Reprod Med Biol. 2019 May 24;18(3):234-240. doi: 10.1002/rmb2.12280. eCollection 2019 Jul. Review.</citation>
    <PMID>31312101</PMID>
  </reference>
  <reference>
    <citation>Guzeloglu-Kayisli O, Kayisli UA, Taylor HS. The role of growth factors and cytokines during implantation: endocrine and paracrine interactions. Semin Reprod Med. 2009 Jan;27(1):62-79. doi: 10.1055/s-0028-1108011. Epub 2009 Feb 5. Review.</citation>
    <PMID>19197806</PMID>
  </reference>
  <reference>
    <citation>Fawzy M, Emad M, Elsuity MA, Mahran A, Abdelrahman MY, Fetih AN, Abdelghafar H, Sabry M, Nour M, Rasheed SM. Cytokines hold promise for human embryo culture in vitro: results of a randomized clinical trial. Fertil Steril. 2019 Nov;112(5):849-857.e1. doi: 10.1016/j.fertnstert.2019.07.012. Epub 2019 Sep 21.</citation>
    <PMID>31551154</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura Integrated Fertility Center</investigator_affiliation>
    <investigator_full_name>Emad Mohamad Sedeek</investigator_full_name>
    <investigator_title>Senior embryologist in IVF laboratory,</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD will be shared</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>6 months after completion and for 3 months</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

